Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 17 November 2025 - 3 December 2025

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Updated December 3, 2025 Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just turned into one of the wildest biotech stories of 2025. After the company reported positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy (DMD) early Wednesday, CAPR stock exploded from roughly $6.36 at Tuesday’s close to around $30 in Wednesday’s trading — a move of about +380%, with intraday highs near $40 and gains at one point exceeding +500%. BioPharma Dive At the same time, Wall Street analysts, regulators and patient advocates are rapidly reassessing both the approval odds and the long‑term
3 December 2025
···
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints.GlobeNewswire Below is a deep dive into today’s news, the regulatory backdrop, the company’s finances and pipeline, and how analysts have been thinking about CAPR stock heading into this inflection point. Key Takeaways Capricor Stock Today: A Biotech Super‑Spike As of early afternoon on December 3, 2025, Capricor Therapeutics (NASDAQ: CAPR) was trading around $39–40 per share, up from approximately $6.36 at the previous close.
3 December 2025
···
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (NASDAQ: PLRZ) has suddenly jumped from obscure micro‑cap to headline mover. On Tuesday, December 2, 2025, the Israeli biotech’s shares spiked roughly 130% in a single session after the company announced a key manufacturing upscaling milestone for its PL‑14 nasal allergy blocker platform. The stock closed at about $7.33 on Tuesday—up from $3.16 the prior session—with intraday highs above $8 and trading volume near 150 million shares. Pre‑market quotes on December 3 show the stock around $6, still dramatically higher than earlier in the week. StockAnalysis+1 The move comes from a tiny base. Polyrizon is a development‑stage biotech
3 December 2025
··
Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Published: December 2, 2025 – For informational purposes only, not investment advice. Key Takeaways Amgen stock is trading around $338.67, slightly higher on the day and still near 52‑week highs after a strong run in 2025. Q3 2025 results beat expectations, with revenue up 12% to $9.6 billion and non‑GAAP EPS comfortably ahead of consensus, prompting a guidance raise for full‑year 2025.AlphaSense+1 Today, December 2, 2025, brought multiple fresh headlines: several institutional investors trimmed AMGN positions, while technical analysts flagged a short‑term bullish setup with support near $330 and resistance around $355.MarketBeat+2MarketBeat+2 Pipeline catalysts are accelerating: Once‑monthly obesity drug MariTide
2 December 2025
··
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

Published: November 29, 2025 ImmunityBio, Inc. (NASDAQ: IBRX) has jumped back onto traders’ and long‑term investors’ radar after a powerful late‑November rally in its share price, driven by blockbuster third‑quarter numbers for its cancer drug Anktiva and a wave of bullish commentary across financial media. On Friday, November 28, ImmunityBio stock closed around the mid‑$2 range after intraday gains of roughly 9–13%, with heavy volume and wide trading ranges highlighted by multiple trader‑focused outlets.Timothy Sykes+2StocksToTrade+2 Yet despite the surge, shares remain down mid‑teens year‑to‑date and far below analysts’ double‑digit price targets. Here’s how the latest news as of November 29,
29 November 2025
···
HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

Hong Kong Exchanges & Clearing Limited (HKEX, stock code 388, ticker 0388.HK) traded slightly higher on Thursday, as investors digested a packed calendar of derivatives expiries, fresh sustainable‑finance headlines and the imminent launch of Hang Seng Biotech Index futures. The move comes against the backdrop of a Hang Seng Index hovering just below 26,000 and a broader Asian equity rally driven by growing expectations of further US rate cuts. BSS+1 HKEX share price on 27 November 2025 According to daily price data from Investing.com, HKEX shares closed around HK$414.80 on 27 November 2025, up roughly 0.4% on the day. The
27 November 2025
··
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics (NASDAQ: SRPT) head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys. SRPT stock today at a glance As of Monday’s close (November 24, 2025), here’s where SRPT stands: In other words, Monday’s bounce was meaningful, but comes after a brutal collapse from triple‑digit levels earlier in 2025. New SRP‑1003 data: a rare bright spot for SRPT stock On Monday, Sarepta released a progress update for
25 November 2025
··
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a Miami‑based preclinical biotech focused on small‑molecule therapies for cancer, aging and age‑related disease, released a new press release highlighting fresh in‑vitro data in human leukemia cells. Finanznachrichten In parallel, investors digested a separate corporate governance update: the company disclosed that board member Dr. Craig Eagle has stepped down, effective November 14, 2025,
21 November 2025
··
Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (NASDAQ: SHPH) surged over 25% in after‑hours and pre‑market trading on November 21, 2025 after an S‑1 filing, recent private placement and Nasdaq compliance update. Here’s what’s driving SHPH stock today. SHPH stock news today: why shares are surging on November 21, 2025 Micro‑cap biotech Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is back on traders’ radar this morning. After closing Thursday’s regular session at $1.83, down 7.6% on the day, Shuttle’s stock spiked to about $2.34 in after‑hours trading, a jump of roughly 28%, after the company’s latest Form S‑1 registration statement hit the SEC’s website. Benzinga+1 The
21 November 2025
··
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On Wednesday, INM shares closed at $1.23, down almost 16% on the day, before surging about 22% after hours to around $1.50.Benzinga That momentum rolled into Thursday’s pre‑market session, where multiple market data sources showed gains of roughly 20–26%, with INM changing hands in the $1.49–$1.55 range on unusually high volume.Benzinga+2RTTNews+2 As regular trading gets underway, real‑time quote providers still show
20 November 2025
··
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after unveiling a trio of significant updates on November 20, 2025: The moves come as Moderna tries to navigate a steep post‑pandemic revenue reset, heavy R&D spending and investor skepticism about how quickly its broad mRNA pipeline can translate into sustainable
20 November 2025
··
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech disclosed that it has secured a sustainable, pharmaceutical‑grade ibogaine supply through its strategic partner PsyLabs, including an initial shipment of 50 kg of high‑potency iboga bark that is now being processed into ibogaine HCl and full‑spectrum Total Alkaloid Extracts for global clinical and therapeutic markets. GlobeNewswire+1 At the same time, Psyence BioMed’s stock was flagged by Benzinga among Thursday’s top
20 November 2025
··
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. (NYSE: NUVB) exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by the successful launch of the company’s lung cancer drug IBTROZI™ (taletrectinib) and a blockbuster third quarter. Investing.com+2Parameter+2 As of early afternoon on November 19, 2025, NUVB was trading around $7.1–$7.2, up roughly 50% on the day from Tuesday’s close near $4.80, on extremely heavy volume. The stock’s 52‑week range has expanded from about $1.54 at the low to over $7.3
19 November 2025
··
Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug Namodenoson, and confirmed that a pivotal Phase III trial in hepatocellular carcinoma (HCC) is now enrolling patients in multiple regions. GlobeNewswire+1 According to real‑time market data, Can-Fite’s American Depositary Receipts (ADRs) traded around $0.47 on November 18, up more than
18 November 2025
··
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1 The real catalyst comes from Roche. Roche’s giredestrant delivers a landmark Phase 3 win Roche’s Genentech unit announced that giredestrant, its investigational oral selective estrogen receptor degrader (SERD), hit the primary endpoint in the Phase 3 lidERA trial in early-stage ER+/HER2- breast cancer. RTT News+1 Key points from today’s breast cancer data: For Olema, none of that is its own data — but it’s
18 November 2025
··
Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025

Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025

On November 17, 2025, Annovis Bio, Inc. (NYSE: ANVS) released new Phase 3 data in early Parkinson’s disease showing that its lead drug candidate buntanetap halted cognitive decline and improved key Alzheimer’s-related biomarkers in a significant subset of patients.Annovis Bio+1 The update triggered a sharp rally in ANVS stock and put fresh attention on the company’s multi-disease neurodegeneration strategy. What Annovis Bio Announced Today Annovis Bio’s news centers on a deeper analysis of its Phase 3 study in early Parkinson’s disease, registered as NCT05357989.Annovis Bio+1 According to the company, buntanetap: In this subgroup with amyloid co‑pathology, patients were found to decline faster
17 November 2025
·
Applied Therapeutics (APLT) Stock Explodes on Heavy Volume as FDA Scrutiny and Cash Concerns Collide – November 17, 2025

Applied Therapeutics (APLT) Stock Explodes on Heavy Volume as FDA Scrutiny and Cash Concerns Collide – November 17, 2025

Applied Therapeutics Inc. (NASDAQ: APLT) is back on traders’ radar today, with its penny stock surging on enormous volume despite intense regulatory uncertainty and a stretched balance sheet. On November 17, 2025, APLT is trading like a biotech rollercoaster: pre‑market gains, intraday spikes of 30–70%, and tens of millions of shares changing hands as investors reassess the company’s prospects after last week’s Q3 update and fresh analyst commentary. Benzinga+2Benzinga+2 Below is a detailed look at everything that matters about Applied Therapeutics today, plus the context behind the move. Key Takeaways 1. What Happened to APLT Today? Pre‑market and intraday action
17 November 2025
·
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. 1. Where the Metsera–Pfizer Deal Stands Today Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion.Reuters+1 Key terms of
17 November 2025
·
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in Ramat Gan, Israel, Galmed Pharmaceuticals Ltd. announced fresh results from its ongoing collaboration with Virginia Commonwealth University (VCU) on overcoming drug resistance in GI cancers. Galmed Pharmaceuticals+1 The headline: A three‑drug combination of Aramchol + Stivarga + metformin produced a synergistic anti‑tumor effect, significantly enhancing GI tumor cell killing both in vitro and in vivo. According to today’s press release
17 November 2025
···
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

All of today’s Autonomix (AMIX) news in one glance – 17 November 2025 As of this afternoon on November 17, 2025, all company‑specific news about Autonomix Medical, Inc. (NASDAQ: AMIX) centers on the same core development: new quality‑of‑life data from its pancreatic cancer PoC 1 study and the stock’s reaction to it. The main headlines are: No additional Autonomix‑specific earnings reports, SEC filings or separate product announcements have been released today beyond coverage of this PoC 1 subgroup analysis and its market impact, based on public news and filings available at the time of writing. Last10K+1 What Autonomix announced today
17 November 2025
·
1 … 8 9 10 11 12 … 15

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop